Trace Amine-Associated Receptor 1 (TAAR1) (TAAR1)

Amine binding sites is a historical and pharmacological term primarily used to describe the Trace Amine-Associated Receptors (TAARs), with TAAR1 being the most prominent therapeutic target in this family. Before the molecular cloning of TAARs in 2001, these sites were identified in the mammalian brain as high-affinity, saturable binding locations for endogenous trace amines such as tyramine, tryptamine, and beta-phenylethylamine. TAAR1 is a G protein-coupled receptor (GPCR) that functions as a key modulator of classical monoaminergic systems, including dopamine, serotonin, and norepinephrine. By regulating the activity and surface expression of monoamine transporters (such as DAT and SERT) and the firing rates of presynaptic neurons, TAAR1 acts as a rheostat for neurotransmission. This makes it a highly attractive therapeutic target for neuropsychiatric disorders, most notably schizophrenia and substance use disorders, where TAAR1 agonists like ralmitaront and ulitarine are being investigated for their ability to normalize dopaminergic signaling without the motor side effects of traditional D2 antagonists. While the term amine binding sites can also refer to imidazoline receptors or specific structural pockets within various proteins, its most significant association in modern drug development is with the TAAR family.

Other names

Amine binding sitesTrace amine binding sitesTA1TAR1Trace amine-associated receptor 1Trace amine receptor 1

Agonism of TAAR1 stimulates cAMP production via Gs protein coupling, which in turn modulates the activity and surface expression of monoamine transporters (DAT, SERT, NET) and regulates the firing rates of dopaminergic and serotonergic neurons.